// App-Quantinova.ai

: Overcoming CD19-Negative Relapses in Patients with B-Cell Lymphomas Treated with Tisagenlecleucel

Researchers

Presenter

  • Guido Ghilardi

Principal Investigators

  • Patrizia Porazzi

  • Ivan Cohen

  • Luca Paruzzo

  • Ositadimma H Ugwuanyi

  • Raymone Pajarillo

  • Yunlin Zhang

  • Puneeth Guruprasad

  • Ruchi P. Patel

  • Elise A. Chong

  • Sunita Dwivedy Nasta

  • Stefan K. Barta

  • Alfred L. Garfall

  • Daniel J. Landsburg

  • Sam Sadigh

  • Mariusz Wasik

  • Jakub Svoboda

  • Siddharth Bhattacharyya

  • Stephen J. Schuster

  • Marco Ruella

Medical Centers

  • Division of Hematology-Oncology, University of Pennsylvania School of Medicine, Philadelphia, PA

  • College of Pharmacy and Institute of Pharmaceutical Science and Technology, Hanyang University, Ansan, Korea, Republic of (South)

  • Lymphoma Program, University of Pennsylvania, Abramson Cancer Center, Philadelphia, PA

  • Department of Pathology, Fox Chase Cancer Center, Philadelphia, PA

  • Department of Oncology, University of Turin, Turin, Italy

  • Center for Cellular Immunotherapies, University of Pennsylvania School of Medicine, Philadelphia, PA

  • Department of Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine, Philadelphia, PA

Locations

  • United States

  • Italy

  • Republic of South Korea

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • B lymphoblastic leukemia

  • B cell lymphomas

  • Lymphomas

Biomarkers

  • B-lymphocyte antigen CD20

  • Coxsackie Virus And Adenovirus Receptor

  • Cluster of differentiation 8A

  • Apparent diffusion coefficient

Drug/Treatment

  • tisagenlecleucel-t

  • CTL019

  • Hydroxyzine

Outcome

  • N/A

Study Design

  • Randomized

  • Efficacy

  • Safety

  • Adaptive

  • Cohort

  • Single Center

Phase

  • I

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved